Interferon beta-1a
Approved · EMAAlso known as Avonex, Rebif, Interferon beta 1-a, Interferon beta 1a+3 more
Avonex, Rebif, Interferon beta 1-a, Interferon beta 1a, Interferon-beta-1a, Interferon beta, recombinant human, Interferon beta-1a (recombinant human).
Recent clinical, regulatory, research and industry developments relating to this drug.
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Rebif is indicated for the treatment of: patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they… Show full indicationShow less
Rebif is indicated for the treatment of: patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis; patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years. Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity.
Indication: Avonex is indicated for the treatment of: patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations… Show full indicationShow less
Avonex is indicated for the treatment of: patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; Avonex slows the progression of disability and decreases the frequency of relapses; patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite MS. Avonex should be discontinued in patients who develop progressive MS.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- The Lancet. Neurology2
- BMC neurology1
- Brain : a journal of neurology1
- Multiple sclerosis (Houndmills, Basingstoke, England)1
- Neurology1
- PloS one1
- Margolin DH5
- Palmer J5
- Coles AJ4
- Compston DA4
- Lake SL4
- Selmaj KW4
- Brinar V3
- Moran S3
- Buffalo Neuroimaging Analysis Center2
- State University of New York at Buffalo2
- University of Cambridge2
- University of North Carolina at Chapel Hill2
- Beckman Center for Molecular Medicine1
- Center for Neuroinflammation and Experimental Therapeutics1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.